Second-line therapy was given according to CWS-2012 relapse protocol and based on the proven ALK-positivity of the tumor, ALK inhibitor crizotinib was permitted as an off-label drug for maintenance therapy for 10 months. This evidence concerns the gene ALK and neoplasm.